CHRS Q3 2024 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$71M-5.1% YoY

Gross Profit

$50M70.7% margin

Operating Income

-$6M-9.0% margin

Net Income

-$11M-15.2% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+8.9%

Cash Flow

Operating Cash Flow

-$62M

Free Cash Flow

-$62M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$505M

Total Liabilities

$593M

Stockholders' Equity

-$88M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$71M	$75M	-5.1%
Gross Profit	$50M	$42M	+19.5%
Operating Income	-$6M	-$32M	+80.0%
Net Income	-$11M	-$40M	+72.9%

Revenue Segments

Product

$71M100%

Product and Service, Other

$220,0000%